These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36612235)

  • 1. Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
    Xia S; Gong H; Zhao Y; Guo L; Wang Y; Zhang B; Sarangdhar M; Noguchi Y; Yan M
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.
    Xia S; Gong H; Wang YK; Liu L; Zhao YC; Guo L; Zhang BK; Sarangdhar M; Noguchi Y; Yan M
    Front Pharmacol; 2023; 14():1129730. PubMed ID: 37007042
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
    Wang Y; Cui C; Deng L; Wang L; Ren X
    Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
    Zhang Y; Fang Y; Wu J; Huang G; Bin J; Liao Y; Shi M; Liao W; Huang N
    Front Pharmacol; 2022; 13():817662. PubMed ID: 35431928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
    Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
    Fan Q; Chen H; Hu Y; Zhao B
    Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
    Ren X; Wang H; Deng L; Wang W; Wang Y
    Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
    Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
    Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wei Q; Wu X
    Front Pharmacol; 2022; 13():986357. PubMed ID: 36408225
    [No Abstract]   [Full Text] [Related]  

  • 13. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
    Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
    Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
    Ebinama U; Sheshadri A; Anand K; Swaminathan I
    J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
    Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
    Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS.
    Chen C; Chen T; Liang J; Guo X; Xu J; Zheng Y; Guo Z; Chi L; Wei L; Chen X; Ye X; He J
    Front Pharmacol; 2021; 12():616505. PubMed ID: 33643048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database.
    Fu Z; Liu J; Zhang C; Hu H; Li S; Zhang Y; You R
    Front Pharmacol; 2024; 15():1383212. PubMed ID: 38948476
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.